SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023)

Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, the incidence is lower and GC represents the tenth most frequent tumor and the seventh cause of cancer mortality. Molecular biology knowledge allowed to better pr...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical & translational oncology Vol. 26; no. 11; pp. 2826 - 2840
Main Authors:	Rivera, Fernando, Longo, Federico, Martín Richard, Marta, Richart, Paula, Alsina, Maria, Carmona, Alberto, Custodio, Ana Belén, Fernández Montes, Ana, Gallego, Javier, Fleitas Kanonnikoff, Tania
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 01-11-2024
Subjects:	Biomarkers, Tumor - analysis Clinical Guides in Oncology Humans Immune Checkpoint Inhibitors - therapeutic use Immunotherapy - methods Medical Oncology - methods Medical Oncology - standards Medicine Medicine & Public Health Oncology Receptor, ErbB-2 - metabolism Spain Stomach Neoplasms - diagnosis Stomach Neoplasms - pathology Stomach Neoplasms - therapy Spain Tumor biology Supportive care Precision medicine Gastric cancer Immunotherapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, the incidence is lower and GC represents the tenth most frequent tumor and the seventh cause of cancer mortality. Molecular biology knowledge allowed to better profile patients for a personalized therapeutic approach. In the localized setting, the multidisciplinary team discussion is fundamental for planning the therapeutic approach. Endoscopic resection in very early stage, perioperative chemotherapy in locally advanced tumors, and chemoradiation + surgery + adjuvant immunotherapy for the GEJ are current standards. For the metastatic setting, biomarker profiling including Her2, PD-L1, MSS status is needed. Chemotherapy in combination with checkpoint inhibitors had improved the outcomes for patients with PD-L1 expression. Her2 positive patients should receive antiHer2 therapy added to chemotherapy. We describe the different evidences and recommendations based on the literature.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Instructional Material/Guideline-3 content type line 23
ISSN:	1699-3055 1699-048X 1699-3055
DOI:	10.1007/s12094-024-03600-7